Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option

BACKGROUND: The availability of a dual sodium glucose co‐transporter 2/dipeptidyl peptidase‐4 inhibitor combination in a single‐tablet combination (STC) represents a new therapeutic option for patients with type 2 diabetes. Empagliflozin/linagliptin STC has been recently approved by the US Food and...

Descripción completa

Detalles Bibliográficos
Autor principal: Woo, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049636/
https://www.ncbi.nlm.nih.gov/pubmed/26303997
http://dx.doi.org/10.1111/ijcp.12720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049636/
https://www.ncbi.nlm.nih.gov/pubmed/26303997
http://dx.doi.org/10.1111/ijcp.12720

Ejemplares similares